MI Sign Up for eTOC Alerts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ho, K. J.
Right arrow Articles by Liao, J. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ho, K. J.
Right arrow Articles by Liao, J. K.
Molecular Interventions 2:219-228 (2002)
© 2002 American Society of Pharmacology and Experimental Therapeutics

Review

Non-nuclear Actions of Estrogen: New Targets for Prevention and Treatment of Cardiovascular Disease

Karen J. Ho, MD and James K. Liao, MD

The Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Cambridge, MA 02139, USA


Gender-based differences in the incidence of hypertensive and coronary artery disease, the development of atherosclerosis, and myocardial remodeling after infarction are attributable to the indirect effect of estrogen on risk factor profiles, such as cholesterol levels, glucose metabolism, and insulin levels. More recent evidence, however, suggests that activated estrogen receptor (ER) mediates signaling cascades that culminate in direct protective effects such as vasodilation, inhibition of response to vessel injury, limiting myocardial injury after infarction, and attenuating cardiac hypertrophy. Although the ER is usually thought of as a ligand-dependent transcription factor, it can also rapidly mobilize signals at the plasma membrane and in the cytoplasm. Thus, a greater understanding of ER function and regulation may lead to the development of highly specific therapeutics that mediate the prevention and treatment of cardiovascular diseases.




This article has been cited by other articles:


Home page
 Mol. Endocrinol.Home page
L. Hu, R. L. Gustofson, H. Feng, P. Ki Leung, N. Mores, L. Z. Krsmanovic, and K. J. Catt
Converse Regulatory Functions of Estrogen Receptor-{alpha} and -{beta} Subtypes Expressed in Hypothalamic Gonadotropin-Releasing Hormone Neurons
Mol. Endocrinol., October 1, 2008; 22(10): 2250 - 2259.
[Abstract] [Full Text] [PDF]

Home page
 J AndrolHome page
R. K. Naz and R. Sellamuthu
Receptors in Spermatozoa: Are They Real?
J Androl, September 1, 2006; 27(5): 627 - 636.
[Full Text] [PDF]

Home page
 BioinformaticsHome page
H. Li and M. Zhan
Systematic intervention of transcription for identifying network response to disease and cellular phenotypes
Bioinformatics, January 1, 2006; 22(1): 96 - 102.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
Y. Merot, F. Ferriere, E. Debroas, G. Flouriot, D. Duval, and C. Saligaut
Estrogen receptor alpha mediates neuronal differentiation and neuroprotection in PC12 cells: critical role of the A/B domain of the receptor
J. Mol. Endocrinol., October 1, 2005; 35(2): 257 - 267.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ASPET Journals Pharmacological Reviews Drug Metabolism and Disposition
Molecular Interventions Molecular Pharmacology J Pharmacology and Exp Therapeutics
Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.